Novavax | NVAX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Adma Biologics USD 64.2M 12.21M 2026-03
Agenus USD -199.08M 22.15M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Cassava Sciences USD 11.17M 2.38M 2026-03
Geron USD 52.07M 6.73M 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
MannKind USD 110.21M 690K 2026-06
Merck USD 15.77B 2.4B 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 960M 817M 2026-06
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Sanofi EUR 9.92B 607M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06